dendritic cell-based immunotherapy (Dendright)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namedendritic cell-based immunotherapy (Dendright)

Drug Alias NameRA-Curcusomedendritic cell-based immunotherapy (Dendright)Rheumavax

ClassificationCell and gene therapy > Cell therapyVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunosuppressantsT lymphocytes inhibitors

TargetsNot applicable

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesDendright

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDendright

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A